When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the industry.
In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, reflects on the gap between sponsor expectations and statistical reality, drawing on lessons from the COVID era to argue for more ...
The U.S. Food and Drug Administration (FDA) issued this week three guidance documents related to clinical trials: a draft guidance on multiregional trials in oncology, a draft guidance on integrating ...
Emulation, simulation, and synthesis represent distinct synthetic-patient paradigms, ranging from reweighted external controls to mechanistic/statistical disease ...
In oncology drug development, using biomarkers to select a study population more likely to benefit from a therapeutic effect is critical to increase the efficiency of a clinical trial in demonstrating ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
In a recent video interview with Applied Clinical Trials, Marc Buyse, ScD, founder and CEO of IDDI, discussed how growing trial complexity is creating new challenges for data conf ...
Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update ...
Introduction Psychedelic-assisted therapy shows promise for treating various mental health conditions; however, its reliance on intensive psychological preparation limits its broader application.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results